Nicholas Coleman

Title: Innovations in Cancer Detection by Nicholas Coleman

Introduction

Nicholas Coleman is a prominent inventor based in Cambridge, GB. He has made significant contributions to the field of cancer detection, holding a total of 6 patents. His work focuses on the detection of dysplastic and neoplastic cells, which are critical in identifying cancerous abnormalities.

Latest Patents

Coleman's latest patents include groundbreaking methods for detecting dysplastic or neoplastic cells using anti-MCM4 and anti-MCM3 antibodies. These patents detail the determination of cellular growth abnormalities, particularly cancerous ones, by detecting target polypeptides or encoding mRNA. The target polypeptides are members of the preinitiation complex of DNA replication, including CDC6, MCM2, MCM3, MCM4, MCM5, MCM6, and MCM7. Test samples for these methods include tissues from various organs such as the cervix, breast, colon, lung, bladder, skin, larynx, esophagus, bronchus, lymph nodes, and urinary tract. Additionally, cells spun from urine, blood, and serum are utilized to determine hematological malignancies and evidence of metastatic sarcoma and carcinoma.

Career Highlights

Throughout his career, Nicholas Coleman has worked with notable organizations, including Cancer Research Technology Limited and Cancer Research Campaign Technology Limited. His innovative approaches have significantly advanced the understanding and detection of cancer.

Collaborations

Some of his notable coworkers include Ronald Alfred Laskey and Gareth Paul Williams. Their collaborative efforts have contributed to the development of effective cancer detection methods.

Conclusion

Nicholas Coleman's work in cancer detection through innovative patent developments has made a lasting impact in the medical field. His contributions continue to pave the way for advancements in cancer diagnostics and treatment.